Investment

What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction?

Pharma's Almanac

Real-World Data

How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?

Pharma's Almanac

Industry Wisdom

What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?

Pharma's Almanac

Roundtable: Artificial Intelligence

In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?

Pharma's Almanac

Roundtable: Patient Centricity

How is an increased focus on patient-centric concerns influencing the way that you work?

Pharma's Almanac

Future of the Industry

What key indicators do you look at to predict the future of this industry?

Pharma's Almanac

Sustainability

What is your plan to build a more sustainable business practice in the coming years?

Pharma's Almanac

2021 Roundup: The Year of Cell and Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Catalent

Gene Therapy

Planning for Success, Addressing Quality Early for Gene Therapies

Maribeth Donovan Janke, Ph.D.

Catalent

Clinical Trial Logistics

Innovative Strategies to Maintain Product Integrity in Biologic and Biosimilar Clinical Studies

Mark Woolf

Catalent

Chemistry, Manufacturing, and Controls

Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization

Matthew Rota; Lisa Caralli; Jim Spavins

Catalent

Cell Therapy

Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology

Catalent

COVID-19 vaccine

How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Partnerships

Graham Brearley, Ph.D.; Jared Davis, Ph.D.

Catalent

Clinical Supply

Getting Your Biologic to Clinic Faster and More Efficiently

Ann McMahon; Pamela Barton

Catalent

COVID-19 Vaccine

Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222

Catalent

Expansion

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

Catalent

COVID-19 Vaccine

Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate

Catalent

FDA Approval

Perrigo and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Version of ProAir® HFA

Perrigo

M&A

Catalent Completes Acquisition of MaSTherCell

Catalent